Chiron Files Infringement Suit in Japan Against Roche On HCV Patent.EMERYVILLE, Calif.--(BW HealthWire)--April 16, 1998--Chiron Corporation (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHIR) announced today that it has filed suit against Nippon Roche K.K. in the Tokyo District Court Tokyo District Court (東京地方裁判所; Tōkyō Chihō Saibansho) is a district court in Kasumigaseki, Chiyoda, Tokyo, Japan. See also
Nippon Roche currently markets hepatitis C polymerase chain reaction polymerase chain reaction (pŏl`ĭmərās') (PCR), laboratory process in which a particular DNA segment from a mixture of DNA chains is rapidly replicated, producing a large, readily analyzed sample of a piece of DNA; the process is (HCV HCV
hepatitis C virus
HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. PCR PCR polymerase chain reaction.
polymerase chain reaction
Polymerase chain reaction (PCR) ) assays. The suit asks for a preliminary injunction to prevent further infringement by Nippon Roche as well as a permanent injunction and unspecified damages.
Chiron scientists cloned HCV in 1987 following five years of research. It was the first time a virus was cloned before it had been grown in tissue culture or otherwise isolated. Since the initial discovery, Chiron has been granted in excess of 100 HCV-related patents in over 20 countries. In 1989, Chiron formed a joint business with Ortho Diagnostics systems, Inc. (Ortho), a Johnson & Johnson Company for immunodiagnostic immunodiagnostic
pertaining to diagnosis by immune reactions. testing for HCV.
With the support of Ortho, Chiron has pursued enforcement of its position against infringers in the HCV immunodiagnostic testing market. Previously, Chiron and Ortho have been granted injunctions against Organon Teknika and International Murex Technologies Corporation (Murex) by the U.K. and Dutch courts. In addition, the Opposition Division of the European Patent Office has upheld the validity of Chiron's basic European HCV patent over the challenge of F. Hoffman LaRoche AG (Roche), the parent of Nippon Roche. Chiron and Ortho currently have a pending legal action in Germany against Roche for infringing the European patent by selling HCV immunoassay kits in Germany. Chiron also has pending legal actions in the U.S. and the Netherlands against Roche for infringing its HCV patents by selling HCV PCR kits in the U.S. and Europe.
Chiron has developed its proprietary Quantiplex(TM) branched DNA DNA: see nucleic acid.
or deoxyribonucleic acid
One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. (bDNA) probe assay to quantitate HCV RNA for use in following the course of disease and monitoring therapy. In Japan, Chiron granted distribution rights to Daiichi Pure Chemicals Co., Ltd. (DPC) for the Quantiplex HCV RNA assay. In 1994, DPC obtained the import license from Koseishou (Ministry of Health and Welfare The Ministry of Health and Welfare is a branch of the government of South Korea. External links
• • ), and has successfully established the HCV quantitative market in Japan.
Chiron Corporation, headquartered in Emeryville, California, USA, near San Francisco, is a leading biotechnology company that combines diagnostic, vaccine, and therapeutic strategies for controlling disease. Chiron participates in three global markets; diagnostics, including immunodiagnostics, critical care diagnostics, and new quantitative probe tests; pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children.
Of or relating to pediatrics. and adult vaccines; and therapeutics, with an emphasis on oncology and infectious diseases. Chiron also has research programs underway in gene therapy, gene transfer, combinatorial chemistry, and recombinant proteins targeted towards oncology, cardiovascular and infectious diseases.
CONTACT: Chiron Corporation
Jim Knighton, 510/923-6055 (Investor Relations)
Judith Rossi, 508/660-4875 (Corporate Communications)